$60.65
+0.76%Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Chief Financial Officer & Treasurer
Compensation
$1,044,331
Chief Human Resources Officer
Chief Information Officer
Chief Legal Officer & Corporate Secretary
Compensation
$978,024
Chief Operating Officer
Compensation
$1,012,690
Chief Regulatory Affairs Officer
Executive Vice President of Merit Medical EMEA
Founder & Chairman
Compensation
$3,248,676
Founder, Chief Executive Officer, President & Chairman
Compensation
$3,248,676
Managing Director of Operation Merit Medical Tijuana
President, Chief Executive Officer & Director
Vice President of Global Communications
During the last 12 months, insiders have purchased $573K and sold $8.84M worth of MMSI shares, resulting in $8.27M of net selling activity.
9.4K
573.29K
5.0K
313.04K
+260K
+$260K
0
0.00
5.0K
450.00K
-450K
-$450K
0
0.00
60.0K
5.19M
-5.2M
-$5.19M
0
0.00
31.0K
2.89M
-2.9M
-$2.89M
Voigt Michel J.
Officer: Chief Human Resources Officer
$136K
Lloyd Brian G.
Officer: Chief Legal Officer, Secretary
$125K
Aronson Martha Goldberg
Director, Officer: President And Ceo
$121K
Smith Christian Adam
Officer: Chief Commercial Officer
$99K
Parra Raul Jr.
Officer: Cfo And Treasurer
$92K
Lampropoulos Fred P.
Director, Officer: Executive Chairman
$6.18M
Parra Raul Jr.
Officer: Cfo And Treasurer
$1.42M
Ward Lynne N.
Director
$785K
Peterson Neil W.
Officer: Chief Operating Officer
$450K
Strong bearish signal with $8.27M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Positive recent trend with net buying activity. Insiders have been accumulating shares in recent months.
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
MMSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 31, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 01, 2025 | April 01, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2024 | April 02, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 04, 2023 | April 04, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | April 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | April 30, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | May 27, 2020 | May 27, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 11, 2019 | May 23, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 13, 2018 | May 24, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 11, 2017 | May 24, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.